Drug Trial Radar · NCT01402882
Clinical Randomisation of an Antifibrinolytic in Significant Head Injury
Last checked: Nov 19, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,737
Actual
Start
Jul 2012
Primary completion
Oct 2019
Study completion Oct 2019
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on mortality and disability in patients with traumatic brain injury. The effect of tranexamic acid on the risk of vascular occlusive events and seizures will also be assessed. Additionally, a nested study will be conducted in a subset of CRASH-3 trial participants. This nested study (CRASH-3 Intracranial Bleeding Sub-Study \[CRASH-3 IBS\]) will examine the effect of tranexamic acid on intracranial haemorrhage and cerebral ischaemia using CT Scans in approximately 1,000 patients randomised into the CRASH-3 trial.
Conditions
- Traumatic Brain Injury
Interventions
Tranexamic AcidDrug
2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome is death in hospital in patients recruited within 3 hours and cause of death will be described.Time frame: within 28 days of injury
Locations
1 site in 1 country. Site status is shown where the registry gives one.
High Technology Medical Center, University Clinic
Tbilisi, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.